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a  b  s  t  r  a  c  t
African  swine  fever  (ASF)  is  an  acute haemorrhagic  disease  of  domestic  pigs  for  which  there  is  currently  no
vaccine.  We  showed  that  experimental  immunisation  of pigs  with  the  non-virulent  OURT88/3  genotype
I  isolate  from  Portugal  followed  by the  closely  related  virulent  OURT88/1  genotype  I isolate  could  confer
protection  against  challenge  with  virulent  isolates  from  Africa  including  the  genotype  I Benin  97/1  isolate
and  genotype  X  Uganda  1965  isolate.  This  immunisation  strategy  protected  most  pigs  challenged  witheywords:
frican swine fever
sfarviridae
igs
rotection
either  Benin  or  Uganda  from  both  disease  and  viraemia.  Cross-protection  was  correlated  with  the  ability  of
different  ASFV  isolates  to  stimulate  immune  lymphocytes  from  the  OURT88/3  and  OURT88/1  immunised
pigs.
© 2011 Elsevier Ltd. Open access under CC BY license.mmunisation
. Introduction
African swine fever (ASF) is a highly contagious, haemorrhagic
isease of pigs caused by a large, cytoplasmic, icosahedral DNA
irus (ASFV) with a genome size of 170–193 kbp. Virulent isolates
ill domestic pigs within 7–10 days of infection. In chronic cases
SF causes respiratory disorders and in some cases swelling around
he leg joints and skin lesions. Domestic pigs can survive infection
ith less virulent isolates and in doing so can gain immunity to
ubsequent challenge with related virulent viruses [1–5].
ASF  is endemic in many sub-Saharan African countries as well
s in Sardinia. In 2007 ASF was introduced into Georgia and from
here spread rapidly to neighbouring countries in the Trans Cauca-
us region, including Southern European Russia [6]. The virus has
ontinued to spread through the Russian Federation and 18 fed-
ral subjects have reported outbreaks (OIE WAHID). Virus has also
een isolated a number of times from wild boar in this region and
he presence of ASF in this wildlife population is likely to make
radication more difﬁcult [6].
∗ Corresponding authors. Tel.: +44 0 1483 232 441; fax: +44 0 1483 232 448.
E-mail addresses: linda.dixon@bbsrc.ac.uk (L.K. Dixon),
aru.takamatsu@bbsrc.ac.uk (H.-H. Takamatsu).
264-410X ©  2011 Elsevier Ltd. 
oi:10.1016/j.vaccine.2011.04.052
Open access under CC BY license.Genotyping of ASFV isolates by partial sequencing of the B646L
gene encoding the major capsid protein p72 has identiﬁed up
to 22 genotypes [7,8]. Many of these are circulating in the long-
established sylvatic cycle involving soft ticks of Ornithodoros spp.
and warthogs in eastern and southern Africa. In many regions the
isolates circulating in domestic pigs are genetically more similar.
Previous  work has shown that pigs are protected from challenge
with related virulent isolates following infection with natural low
virulence isolates and with virus attenuated by passage in tissue
culture or by deletion of genes involved in virulence [2,3,9,10]. Pro-
tection induced by the non-virulent OURT88/3 isolate was shown
to require CD8+ T cells since depletion of these cells was shown
to abrogate this protection [11]. Passive transfer of antibodies from
pigs protected following infection with lower virulence isolates was
also shown to protect naïve pigs from challenge with related viru-
lent virus [12]. Although they are effective in inducing protection,
there are safety issues related to the release of attenuated live vac-
cines. For example, following the introduction of ASF to Spain and
Portugal in 1960, ﬁeld isolate viruses were serially passed through
primary bone marrow or blood macrophage cell cultures and then
used to vaccinate pigs in Spain and Portugal. A substantial pro-
portion of the half million pigs vaccinated in Portugal developed
unacceptable post-vaccination reactions, including death [13]. In
addition, a large number of carrier animals were generated, hin-
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ering subsequent attempts to eradicate the disease [14]. In the
bsence of a vaccine, control measures are currently limited to
laughter and the application of strict animal movement restriction
olicies.
Despite this early experience in Portugal and Spain, the prospect
f developing successful attenuated vaccines have improved as
ubstantial progress has been made in identifying ASFV genes
nvolved in virulence and immune evasion and the complete coding
equences of a number of ASFV isolates are now available [15–17].
his information provides a route to the rational construction of
ttenuated ASFV vaccines. Currently knowledge of the antigens
nvolved in protective immunity and the ability of isolates to confer
ross-protection is limited. In this study we extended our previous
ork with an experimental ASFV vaccination strategy based on
he non-virulent genotype I OURT88/3 isolate from Portugal. We
onﬁrmed that immunisation with this isolate followed by the vir-
lent OURT88/1 isolate confers protection against challenge with
wo virulent isolates from Africa, one, Benin 97/1, from the same
enotype I and the other, virulent Uganda 1965, from genotype X.
e also show that the ability of different ASFV isolates to stimu-
ate IFN- production from the immune pig lymphocytes correlates
ith the ability to induce cross-protection against different isolates.
hus this assay is useful to predict cross-protection and vaccine efﬁ-
acy. These results suggest that ASFV vaccines which cross-protect
ore broadly could be produced, extending the possible use of a
accination strategy.
.  Materials and methods
.1.  ASFV virus isolates
ASFV  isolates used in this study have been described previously
nd included Portuguese isolates of ASFV, OURT88/3 (non-virulent,
on-haemadsorbing, genotype I) and OURT88/1 (virulent, haemad-
orbing, genotype I) [2], virulent Portuguese pig isolate Lisbon
7 (genotype I; [18]), moderately virulent Malta isolate Malta/78
genotype I; [19]), virulent West African isolate Benin 97/1 (geno-
ype I; [15]) virulent African isolates Uganda 1965 (genotype X;
20]) and Malawi Lil 20/1 (genotype VIII; [21]). Viruses were grown
n primary porcine macrophage cultures and used after limited
assage.
.2. Experimental design of pig experiments
Pigs used in the ﬁrst experiment (experiment 1) at IAH Pirbright
aboratory UK were cross-bred pigs, Large White and Landrace,
f average weight 20 kg at the ﬁrst immunisation. For the second
xperiment speciﬁc pathogen free (SPF) Large White pigs were used
rom Anses, Ploufragan, France, SPF facility and were of 15 kg aver-
ge weight at the ﬁrst immunisation (experiment 2). For the third
xperiment (experiment 3) carried out at Anses Ploufragan, France,
arge White pigs were obtained from a local high health status
arm and the average weight at the ﬁrst immunisation was 11 kg.
ll pigs were maintained at high security facilities throughout
he experiment. The ﬁrst experiment at Pirbright was performed
nder Home Ofﬁce licence PPL 70-6369. Experiments at Ploufragan
ere performed according to the animal welfare experimenta-
ion agreement given by the Direction des Services Vétérinaires
es Côtes d’Armor (AFSSA registration number B-22-745-1), under
he responsibility of Marie-Frédérique Le Potier (agreement num-
er 22-17). Brieﬂy, pigs were intramuscularly inoculated with 104CID50 of non-virulent ASFV isolate OURT88/3 and boosted intra-
uscularly 3 weeks later with 104 HAD50 of virulent ASFV isolate of
URT88/1. Pigs were then challenged 3 weeks later with 104 HAD50
f either Benin 97/1 or virulent Uganda 1965 intramuscularly. (2011) 4593– 4600
2.3. Clinical and pathological observations
ASFV-inoculated pigs were monitored for body temperature
and other clinical symptoms and these were recorded and scored
according to the clinical scoring system shown in Supplementary
Table 1. Weight gain was also recorded in the experiments car-
ried out at Ploufragan. All pigs were examined post-mortem either
when the pigs died or at the termination of the experiments. Tissues
were collected for further analysis.
2.4. ASFV detection
Peripheral blood was  analysed at different days post-
immunisation for the presence of ASFV by quantitative PCR (qPCR)
as described previously [22]. Samples which tested positive by qPCR
were further analysed by cytopathic and/or haemadsoption assay
(HAD) using standard pig bone marrow cells in 96 well plate [23,24].
Spleen, tonsil, retropharyngeal and ileocaesal lymph nodes from
post-mortem tissues were also analysed for the presence of ASFV
by qPCR and HAD. Virus detected from tissue samples by qPCR was
expressed as copy number per mg  tissue and by HAD as HAD50.
2.5.  Analysis of immune responses against ASFV
Development of T cell immune responses to ASFV after immu-
nisation was  analysed by IFN- ELISPOT and proliferation assays as
described previously [25]. All ASFV isolates used as antigens for T
cell assays were prepared by culture in porcine bone marrow cells,
and ASFV titres were determined by qPCR [22] and adjusted to give
the equivalent of 105 HAD50/ml. Uninfected porcine bone marrow
culture supernatants were used as negative control antigen.
The  development of ASFV speciﬁc antibodies was analysed using
a competition ASF ELISA kit (INGENASA PPA3 COMPPAC), and the
antibody titre was expressed as log 2 dilution of end point which
gives 50% competition.
3.  Results
3.1. Protection of ASFV immunised pigs from challenge with
virulent  isolates
Three  experiments were carried out in which pigs were immu-
nised with the non-virulent Portuguese OURT88/3 genotype I
isolate followed 3 weeks later by the closely related virulent Por-
tuguese isolate OURT88/1 and then challenged 3 weeks later with
either the West African genotype I isolate, Benin 97/1, or the geno-
type X virulent Uganda 1965 isolate. In the ﬁrst experiment at
Pirbright, 3 immunised pigs and 4 non-immune pigs were chal-
lenged with Benin 97/1. In the second experiment at Ploufragan,
a total of 12 pigs were immunised and challenged with either
Benin 97/1 or virulent Uganda 1965. Ten pigs were prepared as
non-immune controls and challenged with either Benin 97/1 or
virulent Uganda 1965. As a control for weight gain, an extra group
of 5 pigs were included in this experiment. In the third experiment
at Ploufragan, a group of 7 pigs were inoculated and 6 of these and
6 non-immunised pigs were challenged with Benin 97/1.
All  9 immune pigs from experiments 1 and 3 were protected
from challenge with the Benin 97/1 without any clinical signs of
ASF (Figs. 1 and 2). In experiment 2, the 4 immune pigs challenged
with the virulent Uganda 1965 isolate were all protected, although
2 of these pigs showed very short transient pyrexia. However, 2
pigs (1811, 1844) from experiment 2 were not protected follow-
ing challenge with Benin 97/1 (Figs. 1 and 3). Thus the survival
rate of immune pigs challenged with either Benin 97/1 or Uganda
1965 virulent isolates was  100% in two  experiments (Figs. 1 and 3)
and 60% following challenge with Benin 97/1 in experiment 2. In
K. King et al. / Vaccine 29
Fig. 1. Summary results from three separate ASFV challenge/protection experi-
ments. The y-axis shows the percentage of pigs which survived following challenge
and  the x-axis shows time post-challenge in days. Non-immune pig groups chal-
lenged with virulent ASFV are shown as red lines and the challenge virus strain is
indicated as Benin for Benin 97/1, Uganda for virulent Uganda 1965. Immune pigs
challenged are shown as black lines and are labelled imm  + Benin for immunised
pigs  challenged with Benin 97/1 or imm  + Uganda for immunised pigs challenged
with  virulent Uganda 1965. (2011) 4593– 4600 4595
experiment 1, no adverse effects or clinical signs were observed fol-
lowing the immunisation, the boost or challenge. In one pig (VR89)
low copy numbers of virus genome were detected in blood by qPCR,
but not by HAD assay, at 14 days post-boost with OURT88/1 (data
not shown). ASFV was  not detected in any tissues collected from
immune pigs at the termination of the experiment. In contrast, all
the non-immune pigs challenged with Benin 97/1, developed typi-
cal ASF symptoms including high viraemia (∼107 copies of the virus
genome/ml; and up to 8.8 HAD50/ml  virus), and died or were euth-
anized for ethical reasons within 7 days of challenge (Fig. 2A and
B). Post-mortem examination and detection of ASFV from tissues
collected from these animals by qPCR and HAD assay conﬁrmed
severe ASFV infection in the non-immune pigs (up to 107 HAD50/mg
tissue) (see summary in Supplementary Table 2).
In  the second experiment of the 12 immunised pigs, 5 (pig
numbers 1826, 1829, 1834, 1837 and 1845) developed a tran-
sient pyrexia (Supplementary Fig. 1) following immunisation with
OURT88/3. After the OURT88/1 boost, 4 pigs (pig numbers 1809,
1819, 1822 and 1841) developed pyrexia (Supplementary Fig. 1).
Viraemia was  detected from pigs 1819 and 1841 by qPCR and HAD
assays (4.07 × 106 genome copies/ml: 6 HAD50/ml and 6.19 × 103
genome copies/ml: 3.25 HAD50/ml  respectively). Virus genome was
detected at low copy numbers by qPCR in blood samples from an
additional 2 pigs but these were negative by HAD assay. Pigs 1819,
1822 and 1841 were terminated for ethical reasons between day 4
and day 6 post boost with OURT88/1 before the potential develop-
ment of severe ASF symptoms.
Because  of the loss of pigs after the OURT88/1 boost, only four
pigs were subsequently challenged with virulent Uganda 1965. Two
of these developed transient pyrexia and low viraemia. Pig 1834
had a temperature at day 6 of 40.3 ◦C, and the virus genome was
detected at 227 copies/ml and virus at 1.75 HAD50/ml; pig 1845
had a temperature at day 7 of 40.6 ◦C and the virus genome was
detected at 633 copies/ml; and virus at 2 HAD50/ml. The other two
pigs challenged with virulent Uganda 1965 isolate showed no clin-
ical signs and no virus was  detected in blood by qPCR or HAD assay.
Five pigs were challenged with Benin 97/1, two pigs (1811, 1844)
developed typical ASF (Fig. 3C and D) and were terminated at days
6 and 7 respectively before developing severe disease. The remain-
ing pigs (1809, 1829, 1837) did not develop pyrexia or other ASF
clinical signs but occasionally virus genome was detected by qPCR
at concentrations up to 323 copies/ml but virus was not detected
by HAD assay.
The  two groups of naïve pigs challenged with either virulent
Uganda 1965 or Benin 97/1 all developed severe clinical signs of ASF
with high viraemia (up to 5.37 × 107 genome copies/ml; virus up
to 7.25 HAD50), and either died or were terminated within 8 days
of challenge (Fig. 3). Post-mortem examination conﬁrmed severe
ASF in these control pigs (see summary in Supplementary Table
2).
In the third experiment, 7 immune pigs were generated and 6
of these were challenged with Benin 97/1. One pig (474) showed
pyrexia from 2 weeks after the ﬁrst immunisation (Supplementary
Fig. 1C). This pig was  euthanised before the OURT88/1 boost. Post-
mortem examination of this pig revealed a dark enlarged spleen
characteristic of ASFV infection and virus DNA was  detected from
the spleen and retropharyngeal lymph node (RLN) by qPCR (8790
and 41000 virus genome copies/mg tissue respectively) and by
cytopathic effect in cultures of porcine macrophages. HAD was not
observed in these cultures, indicating that the replicating virus was
non-HAD, as expected for the OURT88/3 isolate. Six pigs each of
the immune and non-immune groups were challenged with Benin
97/1. All of the immunised pigs were protected from challenge
without showing any clinical signs or development of viraemia
(Fig. 2C and D). Low copy numbers of the virus genome were
detected by qPCR, but not HAD, in spleen and RLN of pig 55 at
4596 K.  King et al. / Vaccine 29 (2011) 4593– 4600
Fig. 2. Clinical scores and viraemia from experiment 1 (A and B) and experiment 3 (C and D). Clinical scores for experiment 1 are shown as the mean of the group in panel
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r and those from experiment 3 in panel C. Red lines indicate non-immune pigs a
xperiments 1 and 3 are shown in panels B and D respectively and expressed as A
olour in this ﬁgure legend, the reader is referred to the web version of this article.)he termination of the experiment but not in any other lymphoid
issues and blood in this pig, or in any tissues from the other immu-
ised and challenged pigs. In contrast, high copy numbers of virus
enome and of virus were detected in blood (up to 5.62 × 108
ig. 3. Clinical score (A and C) and viraemia estimated by qPCR (B and D) of individual pi
965 (A and B), or Benin 97/1 (C and D) isolates are shown in black lines. Results from no
ed  lines. Two  immune pigs (#1811: black circle; #1844: black square) were not protecteck lines indicate immune pigs. Viraemia estimated by qPCR for individual pigs in
enome copy number per ml  blood (log10). (For interpretation of the references tovirus genome copies/ml; virus up to 8.3 HAD50/ml) and tissues
(virus ∼7 HAD50/mg  of tissue) were detected from all lymphoid
tissues in all of the non-immune pigs challenged (see summary in
Supplementary Table 2).
gs from experiment 2. Results from immune pigs challenged with virulent Uganda
n-immune control pigs challenged with Benin 97/1 or Uganda 1965 are shown as
d from Benin 97/1 challenge (C and D).
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Fig. 4. Development of anti-ASFV T cell responses after OURT88/3 immunisation, assessed by IFN- ELISPOT (A–C) and proliferation assays (D–F) from experiment 1. Pig
peripheral blood lymphocytes were stimulated ex vivo with either OURT88/3 (open circle) or Benin 97/1 (open square). Background levels of the ELISPOT assays are shown
in  black open triangles. ELISPOT results are shown as IFN- production per one million lymphocytes, and proliferation assays are displayed as [3H] thymidine uptake (cpm
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cexperimental cpm − BG cpm]). The x-axis shows days post the ﬁrst ASFV inoculat
rrowhead indicates the time of OURT88/1 boost and the open arrowhead indicates
Unlike the non-immune pigs, immune pigs challenged increased
heir body weight during the challenge (Supplementary Fig. 2).
.2. Measurement of ASFV speciﬁc T cell and antibody responses
n  immunised pigs
Lymphocytes from immunised pigs in experiment 1 were col-
ected at various times post-immunisation and IFN- ELISPOT
nd proliferation assays were performed with OURT88/3 or Benin
7/1 as antigen. In all 3 pigs, the numbers of ASFV speciﬁc IFN-
roducing cells was rapidly increased after the OURT88/3 inoc-
lation and further increased after the OURT88/1 boost. Both
URT88/3 and Benin 97/1 isolates stimulated lymphocytes from
mmunised pigs to an approximately equal amount (Fig. 4A–C).
ow levels of proliferation were detected in all pigs at 1 or weeks post-OURT88/3 inoculation, but the amount of prolif-
ration was dramatically increased after the OURT88/1 boost
Fig. 4D–F). In two of the pigs (Fig. 4D and E) levels of T
ell proliferative responses dropped following challenge withhe arrow on each graph indicates the time of OURT88/3 immunisation, the black
enin challenge.
Benin  97/1 isolate and in the other pig levels continued to rise
(Fig. 4F).
At  the termination of the experiment, lymphocytes from these
pigs were tested for cross-reactivity stimulated with various ASFV
isolates by IFN- ELISPOT assays (Fig. 5A). Immune lympho-
cytes from all 3 pigs responded similarly to OURT88/3, OURT88/1
and Benin 97/1. Lymphocytes from two pigs (VR89, VR90) also
responded well to genotype 1 isolate Malta 78 and genotype X iso-
late Uganda 1965 and lymphocytes from pig VR90 also responded
well to genotype I isolate Lisbon 57. Lymphocytes from pig VR92
responded less well to Malta 78, Uganda 1965 and Lisbon 57 and
those from pig VR89 also showed a reduced response to Lisbon 57.
No cross-reactivity was  observed to genotype VIII isolate Malawi
Lil 20/1.
In  the second experiment (Fig. 5B), lymphocytes were collected
from pigs just prior to challenge. Lymphocytes from 2 of the immu-
nised pigs (1829, 1837) showed a much stronger response in IFN-
ELISPOT assays against OURT88/1 and Benin 97/1 than the other 3
immunised pigs (1809, 1811, 1844). Interestingly, 2 of the pigs from
4598 K.  King et al. / Vaccine 29 (2011) 4593– 4600
Fig. 5. ASFV isolate cross-reactivity measured by IFN- ELISPOT assays. The pigs
from experiment 1 (VR89, VR90, VR92) which were protected from challenge with
Benin 97/1 isolate were used as immune lymphocytes donors for the ex vivo IFN-
ELISPOT assay following stimulation of the lymphocytes with various ASFV isolates.
Results are shown as % cross-reactivity compared to the OURT88/3 stimulation.
Panel  B shows the stimulation of lymphocytes from pigs in experiment 2. Immu-
nised  pigs (1809, 1811, 1829, 1837, 1844) and non-immune control pigs (1806,
1816, 1825) peripheral blood mononuclear cells collected a day before challenge
were  stimulated ex vivo with either medium alone, OURT88/1 or Benin 97/1. Results
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Fig. 6. Anti-ASFV VP72 antibody responses following immunisation from experi-
ment 2 (A and B) and experiment 3 (C). Antibody titre was measured by competitive
ELISA  in serial dilution (log2) giving 50% inhibition. Groups of pigs from experiment
2  challenged with Uganda 1965 are shown in A and challenged with Benin 97/1 in
B. A group of pigs from experiment 3 challenged with Benin 97/1 is shown in C.re shown as IFN- production per one million lymphocytes. The x-axis shows the
ig number.
hich lymphocytes responded least (1811, 1844) in IFN- ELISPOT
ssays (Fig. 5B) were those which were not protected against Benin
7/1 challenge (Fig. 3C and D). No response was observed in IFN-
LISPOT assays when lymphocytes from non-immune pigs 1806,
816, 1825 (Fig. 5B) were stimulated with ASFV, conﬁrming the
peciﬁcity of the assay. In the third experiment IFN- ELISPOT assay
as carried out using lymphocytes collected prior to challenge and
he results were too high to be read accurately by the ELISPOT
eader (data not shown). This indicates that strong T cell immunity
as induced in all pigs before the challenge.
A competitive ELISA based on the p72 major capsid protein was
sed to measure development of anti-ASFV speciﬁc antibodies. The
esults from analysis of sera collected in experiment 2 and 3 are
hown in Fig. 6. An antibody response developed in all pigs immu-
ised with OURT88/3 followed by OURT88/1 boost, except pig 76
rom experiment 3 in which antibody against p72 was not detected
rior to boost (Fig. 6C). The levels of anti-ASFV antibody gradually
ncreased and were boosted by the OURT88/1 inoculation. Interest-
The arrow on each graph indicates the time of OURT88/3 immunisation, the black
arrowhead indicates the time of OURT88/1 boost and the open arrowhead indicates
the challenge. Red line/symbol indicates pigs not protected from challenge and/or
lost at immunisation procedures.
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ngly, the antibody levels in the 2 pigs which were not protected
rom Benin 97/1 challenge in experiment 2 (Fig. 6B) had either the
ighest (1844) or the lowest (1811) anti-ASFV antibody titre before
he challenge. On the other hand pig 184 from experiment 3 had a
uch lower antibody titre at challenge (day 41) than these unpro-
ected pigs in experiment 2, but was protected. The pig which was
uthanized following boost (1822) had the lowest antibody titres
t the time of boost (Fig. 6B), in contrast pig 76 from experiment
 was protected from OURT88/1 boost despite a lack of apparent
ntibody response (Fig. 6C).
. Discussion
In this study we have demonstrated that experimental immu-
isation of pigs with a non-virulent ASFV genotype I isolate from
ortugal, OURT88/3, followed by a boost with a closely related
irulent isolate, OURT88/1, can induce protective immunity in
uropean domestic pigs against challenge from two  virulent African
solates of ASFV. These included a genotype I isolate from West
frica, Benin 97/1 and a genotype X isolate from Uganda, viru-
ent Uganda 1965. Overall 85.7% and 100% pigs were protected
rom Benin 97/1 and Uganda 1965 ASFV challenge respectively.
ore than 78% of pigs challenged with Benin 97/1 and 50%
f pigs challenged with Uganda 1965 were completely pro-
ected by not showing any sign of disease or development of
iraemia.
Phylogenetic analysis of the concatenated sequences of 125
enes conserved between 12 complete genome sequences showed
hat the OURT88/3 and Benin 97/1 sequences are greater than
5% identical across these genes [15,16]. Although the virulent
ganda 1965 isolate is placed in VP72 genotype X, it falls within the
ame clade as the genotype I isolates (Chapman et al., unpublished
bservations). This is the ﬁrst clear demonstration of induction of
ross-protective immunity against challenge with more distantly
elated virulent strains of ASFV. It has been reported previously
hat the pigs which recover from less virulent strains of ASFV are
esistant to challenge with the same or very closely related virus
trains [1,3,14]. The genotypes of the strains used in these studies
ere not deﬁned.
The  ASFV OURT88/3 strain was isolated from Ornithodoros
rraticus ticks in Portugal and described not to cause clinical signs
r viraemia [2]. Interestingly, the inoculation of virulent OURT88/1
irus following OURT88/3 immunisation, could protect pigs from
he disease, and also further stimulated development of anti-
SFV immune responses. This indicates that the inoculation of
URT88/1 acts to boost the immune response (Figs. 4 and 6) and
his might be required for inducing sufﬁcient ASFV isolate-cross-
rotective immunity. However, further experiments are required
o clarify this. Measurement of ASFV speciﬁc IFN- responses
x vivo, with different ASFV isolates, showed various degrees
f cross-reactivity and this correlated well with cross-protection
nduced in vivo. Good cross-reactivity against genotype X iso-
ate virulent Uganda 1965 (Fig. 5A) was observed, and this is
he reason why pigs were challenged with virulent Uganda 1965
n experiment 2. As predicted from this ex vivo assay, all of
he pigs immunised and challenged with virulent Uganda 1965
irus were protected. No cross-reactivity to genotype XIII iso-
ate Malawi LIL 20/1 was detected and this correlates with the
bservation that OURT88/3 and OURT88/1 immunised pigs are
ot protected from Malawi LIL 20/1 challenge [2,Denyer et al.
npublished observation]. Taken together these data suggest that
his ex vivo, IFN- ELISPOT assay might be a useful tool to assess
accine efﬁcacy and/or to assess possibility of ASFV isolate-cross-
rotection.
An anti-ASFV antibody response also developed after OURT88/3
mmunisation and was boosted after the OURT88/1 inoculation. The (2011) 4593– 4600 4599
anti-ASFV antibody titre was measured by a p72 competition ELISA,
however we  could not conclude from these experiments whether
the level of antibody developed by our immunisation protocol is
either sufﬁcient or necessary for protection.
OURT88/3 has been used as a vaccine model to identify what is
required for inducing ASFV protective immunity in domestic pigs.
The observations of adverse effects of OURT88/3 immunisation in
some of the pigs vaccinated in France suggest that further attenua-
tion of this isolate by deleting additional genes or possibly changing
the dose or route of vaccination may  be useful. Secondly, the results
from experiment 2 showed that our current protocol did not induce
complete protection in all of the pigs immunised with the virulent
OURT88/1 boost. This may  be due to the genetic background of the
pigs as we have previously demonstrated that cc inbred pigs are
also not always protected by OURT88/3 from OURT88/1 challenge
[11]. It is possible that the age and/or size of pigs at the time of the
ﬁrst immunisation may  be important for the induction of complete
protection since the pigs used in France were smaller and younger
than those used at Pirbright. It will also be useful in future to com-
pare the effects of boosting with the non or low virulent OURT88/3
since this would help to avoid adverse effects resulting from boost-
ing with virulent OURT88/1. Our observation that cross-protection
can be induced between different genotypes is important since this
suggests when an ASFV vaccine is developed, its practical use in
the ﬁeld is likely to be extended in areas where several genotypes
are present. Additional experiments are required to establish the
extent of cross-protection.
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